Prominent publications by David A Cooper

KOL Index score: 18549

OBJECTIVE: Metabolic syndrome is a cluster of risk factors for cardiovascular disease and type 2 diabetes. Definitions exist to identify those "at risk." Treatment of HIV infection with highly active antiretroviral therapy can induce severe metabolic complications including lipodystrophy, dyslipidemia, and insulin resistance. The purpose of this study was to report the prevalence of metabolic syndrome in HIV-infected patients and compare insulin resistance and total body, limb, and ...

Also Ranks for: Metabolic Syndrome |  insulin resistance |  active antiretroviral |  infected patients |  body fat
KOL Index score: 18085

BACKGROUND: The week 48 primary analysis of the ENCORE1 trial established the virological non-inferiority and safety of efavirenz 400 mg compared with the standard 600 mg dose, combined with tenofovir and emtricitabine, as first-line HIV therapy. This 96-week follow-up of the trial assesses the durability of efficacy and safety of this treatment over 96 weeks.

METHODS: ENCORE1 was a double-blind, placebo-controlled, non-inferiority trial done at 38 clinical sites in 13 countries. ...

Also Ranks for: Efavirenz 400 |  viral load |  96 weeks |  encore1 study |  hiv therapy
KOL Index score: 17723

CONTEXT: Current guidelines recommend that individuals infected with the human immunodeficiency virus type 1 (HIV-1) be treated using combinations of antiretroviral agents to achieve sustained suppression of viral replication as measured by the plasma HIV-1 RNA assay, in the hopes of achieving prolonged remission of the disease. However, until recently, many drug combinations have not led to sustained suppression of HIV-1 RNA.

OBJECTIVE: To compare the virologic effects of various ...

Also Ranks for: Nevirapine Zidovudine |  hiv1 rna |  incas trial |  triple drug therapy |  infected patients
KOL Index score: 17281

OBJECTIVE: To describe a syndrome of peripheral lipodystrophy (fat wasting of the face, limbs and upper trunk), hyperlipidaemia and insulin resistance in patients receiving potent HIV protease inhibitor therapy.

DESIGN: Cross-sectional study.

SETTING: Outpatient clinic of a university teaching hospital.

PATIENTS: HIV-infected patients either receiving at least one protease inhibitor (n=116) or protease inhibitor-naive (n=32), and healthy men (n=47).


Also Ranks for: Peripheral Lipodystrophy |  insulin resistance |  hiv protease |  triglyceride levels |  body composition
KOL Index score: 16422

BACKGROUND: Treatment options for HIV-1 infected individuals who have received extensive previous antiretroviral therapy are limited. We compared efficacy and safety of the novel non-peptidic protease inhibitor tipranavir co-administered with ritonavir plus an optimised background regimen with that of an investigator-selected ritonavir-boosted comparator protease inhibitor (CPI-ritonavir) in such patients.

METHODS: We did a combined analysis of 48-week data from two ongoing, randomised, ...

Also Ranks for: 48 Weeks |  viral drug |  randomized evaluation |  infected patients |  background regimen
KOL Index score: 16200

CONTEXT: Abacavir, a nucleoside analogue, has demonstrated suppression of human immunodeficiency virus (HIV) replication alone and in combination therapy. However, the role of abacavir in a triple nucleoside combination regimen has not been evaluated against a standard protease inhibitor-containing regimen for initial antiretroviral treatment.

OBJECTIVE: To evaluate antiretroviral equivalence and safety of an abacavir-lamivudine-zidovudine regimen compared with an ...

Also Ranks for: 400 Copies |  naive hiv |  infected adults |  48 weeks |  lamivudine zidovudine
KOL Index score: 16186

BACKGROUND: The T-20 vs. Optimized Regimen Only Study 2 (TORO 2) compared the efficacy and safety of 24 weeks of treatment with the fusion inhibitor enfuvirtide in combination with an optimized background antiretroviral regimen with the efficacy and safety of the optimized background regimen alone.

METHODS: The patients had previous treatment with each of the three classes of antiretroviral drugs, documented resistance to each class, or both and a plasma level of human immunodeficiency ...

Also Ranks for: Milliliter Control |  background regimen |  cubic millimeter |  enfuvirtide patients |  antiretroviral drugs
KOL Index score: 15146

BackgroundThe New South Wales (NSW) HIV Strategy 2016–2020 aims for the virtual elimination of HIV transmission in NSW, Australia, by 2020. Despite high and increasing levels of HIV testing and treatment since 2012, the annual number of HIV diagnoses in NSW has remained generally unchanged. Pre-exposure prophylaxis (PrEP) is highly effective in preventing HIV infection among gay and bisexual men (GBM) when taken appropriately. However, there have been no population-level studies that ...

Also Ranks for: New South Wales |  exposure prophylaxis |  risk hiv |  prep implementation |  single arm
KOL Index score: 15017

BACKGROUND: Zidovudine therapy is of benefit in the treatment of symptomatic and asymptomatic human immunodeficiency virus (HIV) infection in persons with CD4+ cell counts of less than 500 per cubic millimeter. The efficacy, safety, and duration of benefit of zidovudine in those with 500 or more CD4+ cells per cubic millimeter are uncertain.

METHODS: In a double-blind, placebo-controlled trial, 993 patients with asymptomatic HIV infection and CD4+ cell counts above 400 per cubic ...

Also Ranks for: Cubic Millimeter |  asymptomatic hiv infection |  cell counts |  disease progression zidovudine |  studies hiv
KOL Index score: 14929

BACKGROUND: To reduce lipid abnormalities and other side-effects associated with antiretroviral regimens containing lopinavir-ritonavir, patients might want to switch one or more components of their regimen. We compared substitution of raltegravir for lopinavir-ritonavir with continuation of lopinavir-ritonavir in HIV-infected patients with stable viral suppression on lopinavir-ritonavir-based combination therapy.

METHODS: The SWITCHMRK 1 and 2 studies were multicentre, double-blind, ...

Also Ranks for: Lopinavir Ritonavir |  patients raltegravir |  based regimen |  baseline week |  stable hiv
KOL Index score: 14724

OBJECTIVE: To examine the impact of viral hepatitis co-infection on HIV disease outcomes following commencement of combination antiretroviral therapy in a developing country setting.

METHODS: HIV RNA suppression, CD4 cell count recovery, and HIV disease progression were examined within a cohort of Thai HIV-infected patients enrolled in eight HIV-NAT randomized controlled trials of antiretroviral therapy (n = 692). Hepatitis B virus (HBV) and hepatitis C virus (HCV) testing was performed ...

Also Ranks for: Viral Hepatitis |  hiv disease |  hbv hcv |  cd4 count
KOL Index score: 14599

The latent HIV reservoir is a major impediment to curing HIV infection. The contribution of CD4(+) T cell activation status to the establishment and maintenance of the latent reservoir was investigated by enumerating viral DNA components in a cohort of 12 individuals commencing antiretroviral therapy (ART) containing raltegravir, an integrase inhibitor. Prior to ART, the levels of total HIV DNA were similar across HLA-DR(+) and HLA-DR(-) (HLA-DR(±)) CD38(±) memory CD4(+) T cell ...

Also Ranks for: Hiv Dna |  antiretroviral therapy |  memory cd4 |  latent reservoir |  resting cells
KOL Index score: 14486

OBJECTIVE: To assess the safety of 2 intermittent treatment strategies compared with continuous therapy for patients with virologic suppression on highly active antiretroviral therapy (HAART) at baseline.

DESIGN: Seventy-four nucleoside reverse transcriptase inhibitor (NRTI) and protease inhibitor (PI) pretreated patients with an HIV RNA level <50 copies at screening were randomized to continuous treatment, CD4-guided treatment, or week-on-week-off treatment with 2 NRTIs plus 1600 mg/100 ...

Also Ranks for: Continuous Haart |  antiretroviral therapy |  cd4 count |  50 copies |  hiv rna
KOL Index score: 14310

BACKGROUND: Uncertainty exists about the best treatment for people with HIV-1 who have virological failure with first-line combination antiretroviral therapy of a non-nucleoside analogue (NNRTI) plus two nucleoside or nucleotide analogue reverse transcriptase inhibitors (NtRTI). We compared a second-line regimen combining two new classes of drug with a WHO-recommended regimen.

METHODS: We did this 96-week, phase 3b/4, randomised, open-label non-inferiority trial at 37 sites worldwide. ...

Also Ranks for: Virological Failure |  transcriptase inhibitors |  boosted lopinavir |  48 weeks |  primary endpoint
KOL Index score: 14069

T follicular helper (Tfh) cells are a specialized subset of memory CD4(+) T cells that are found exclusively within the germinal centers of secondary lymphoid tissues and are important for adaptive antibody responses and B cell memory. Tfh cells do not express CCR5, the primary entry coreceptor for both human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus (SIV), and therefore, we hypothesized that these cells would avoid infection. We studied lymph nodes and ...

Also Ranks for: Lymphoid Tissues |  pigtail macaques |  simian immunodeficiency |  follicular helper |  tfh cells

Key People For Antiretroviral Therapy

Top KOLs in the world
Andrew * *********
antiretroviral therapy viral load hiv infection
Jens ******* ********
antiretroviral therapy hiv infection viral load
Peter ******
antiretroviral therapy hiv infection myocardial infarction
David * ******
antiretroviral therapy hiv infection viral load
Joseph * ****
antiretroviral therapy united states hiv infection
Douglas * ********
antiretroviral therapy hiv infection human immunodeficiency virus

David A Cooper:Expert Impact

Concepts for whichDavid A Cooperhas direct influence:Antiretroviral therapy,  Hiv infection,  Viral load,  Human immunodeficiency virus,  Hiv infections.

David A Cooper:KOL impact

Concepts related to the work of other authors for whichfor which David A Cooper has influence:Antiretroviral therapy,  Hiv infection,  Human immunodeficiency virus,  Viral load,  Protease inhibitors,  Infected patients,  Highly active.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

Immunovirology and Pathogenesis Program, The Kirby Institute, Randwick, New South Wales, Australia. | Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia. | The Kirby Institute, UNSW Australia, Sydney, Australia. | Centre for Applied Med